Back to journals
Academic Journal

Research Square

15 Papers Indexed in Blossom

Data updated

Research Footprint

Research Square has 15 tracked papers indexed in Blossom (2021–2026) from 123 authors, most often covering Psilocybin, MDMA and Ibogaine, across Depressive Disorders, Anxiety Disorders and Substance Use Disorders (SUD).

Published Papers

Open Accessindividual

Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes

This reanalysis of a six-week double-blind randomised controlled trial compared psilocybin with escitalopram in adults with moderate-to-severe depression and found sex-specific patterns in response. Women given psilocybin had greater reductions in anxiety, while women given escitalopram had greater reductions in anhedonia; other differences were small and uncertain.

Published
Journal
Research Square
Authors
Frick, A., Blest-Hopley, G., Grin, M., Erritzoe, D., Nutt, D., Carhart-Harris, R.
Open Accessindividual

Indication-stratified mortality risk of ibogaine treatment under contemporary safety protocols: a multisite analysis of 19,071 patients and updated systematic review of fatalities

This retrospective multisite study (n=19,071) and updated systematic review of fatalities found that deaths after ibogaine treatment were rare overall and occurred only in people treated for opioid use disorder, with none among non-SUD patients. The review of reported fatalities showed the same pattern, suggesting the mortality risk is concentrated in opioid detoxification rather than other uses.

Published
Journal
Research Square
Authors
Arns, M., Shinozuka, K., Barsuglia, J.
Open Accessindividual

DMT, Madness, and Healing: Psychosis Model, Therapy Model, and Their Relations to Mystical Experiences and Positive Emotionality

This randomised, placebo-controlled, double-blind crossover study (n=25) found that DMT (60 mg) increased psychotic-like experiences and suggestibility in healthy volunteers, alongside strong mystical and other psychedelic effects. The links between these effects appeared to be driven more by positive emotionality than by mystical experience alone.

Published
Journal
Research Square
Authors
Wießner, I., Falchi-Carvalho, M., Laborde, S., Barros, H., Bolcont, R., Medina, M., Mograbi, D., Coelho, N. G., Palhano-Fontes, F., Araujo, D.
Open Accessindividual

When Therapy Falls Short: A Qualitative Study of Psychotherapy After Challenging Psychedelic Experiences

This qualitative study (n=35) explored psychotherapy experiences after challenging naturalistic psychedelic experiences and found that many people felt misunderstood, judged, or poorly supported by therapists. Participants often hid their distress, turned to self-directed support, and described a mismatch between their recovery pace and clinicians’ expectations.

Published
Journal
Research Square
Authors
Simon, G., Tadmor, N., Evans, J., Luke, D., Luoma, J.
Open Accessindividual

Extended difficulties after psychedelic experiences: Prevalence and associations in a global, multilingual sample

This survey study (n=6,476) examined long-lasting difficulties after psychedelic use in a global multilingual sample and found that nearly half reported problems lasting at least 24 hours, with existential struggle, depression and derealisation most common. About 28% reported disruptive difficulties lasting at least a month, which were linked to younger age, lower income, less family support, lower emotional stability and higher pre-existing anxiety or depression.

Published
Journal
Research Square
Authors
Oliver, C. R., Luke, D., Evans, J., Jacob, S. A., Johnson, M., Lake, S., Kruger, D., Kevin, F. B., Lucas, P.
Open Accessindividual

Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC

This rat study found that the ibogaine-derived compound oxa-noribogaine reduced alcohol drinking and relapse-like drinking by strengthening learning from negative drinking outcomes and changing glutamatergic activity in the prefrontal cortex. It also appeared to match or exceed ibogaine’s effects without detectable motor or cardiac problems.

Published
Journal
Research Square
Authors
Meinhardt, M., Skorodumov, I., Walter, F., Akan, M., Buchborn, T., PRIEULT, Y. L., Urban, M., Spanagel, R., von Ammon, L., Hopf, C., Kalinichenko, L., Mueller, C., Winter, C., Hadar, R., Gül, A. Z., Massuda, B., Hildebrandt, M., Domi, E., Keshishian, A., Ciccocioppo, R., Sames, D., Havel, V., Woods, L., Beeson, A.

Quick Facts

Papers Indexed
15
Publisher
Springer Nature
Website
Visit